A61K 47/66
The modifying agent being a pre-targeting system involving a peptide or protein
Official title: the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K47/66 (The modifying agent being a pre-targeting system involving a peptide or protein) appears on 379 US grants and 554 published applications in this corpus.
Search patents in A61K- Granted patents
- 379
- Published applications
- 554
- Assignees
- 341
- Inventors
- 1,079
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 4 | 0 |
| 1999 | 10 | 0 |
| 2000 | 8 | 0 |
| 2001 | 8 | 1 |
| 2002 | 8 | 9 |
| 2003 | 7 | 33 |
| 2004 | 6 | 30 |
| 2005 | 3 | 27 |
| 2006 | 10 | 25 |
| 2007 | 15 | 25 |
| 2008 | 11 | 28 |
| 2009 | 13 | 22 |
| 2010 | 19 | 26 |
| 2011 | 22 | 29 |
| 2012 | 13 | 20 |
| 2013 | 16 | 15 |
| 2014 | 21 | 20 |
| 2015 | 13 | 27 |
| 2016 | 23 | 21 |
| 2017 | 15 | 12 |
| 2018 | 17 | 23 |
| 2019 | 14 | 31 |
| 2020 | 18 | 26 |
| 2021 | 10 | 21 |
| 2022 | 10 | 16 |
| 2023 | 14 | 19 |
| 2024 | 8 | 24 |
| 2025 | 19 | 14 |
| 2026 | 9 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for treatment of dry eye comprising applying P55PIK inhibitor22 Sep 2026US 12,741,988 B2Han Yicheng Biological Technology Co, Ltd.
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- Bi-specific fusion proteins25 Aug 2026US 12,715,937 B2Silver Creek Pharmaceuticals, Inc.
- Bi-specific fusion proteins4 Aug 2026US 12,698,347 B2Silver Creek Pharmaceuticals, Inc.
- Nanoparticle and use thereof for the combinatorial therapy of endoplasmic reticulum stress inducer and immunotherapeutic to tumors and immune cells16 Jun 2026US 12,653,903 B2National Yang Ming.Chiao Tung University
- Protein-drug conjugates comprising camptothecin analogs and methods of use thereof10 Sep 2026US 2026/0263625 A1Regeneron Pharmaceutical, Inc.
- Lysosomal targeting bifunctional molecules for degradation of autoantibodies6 Aug 2026US 2026/0224719 A1Lycia Therapeutics, Inc.
- Lysosome-Mediated Degradation of Extracellular Proteins16 Jul 2026US 2026/0199495 A1Washington University
- Cancer immunotherapies to promote hyperacute rejection2 Jul 2026US 2026/0183409 A1Cornell University
- Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer4 Jun 2026US 2026/0151501 A1Abtis Co., Ltd.
Most cited
By later US patents
- Method for enhancing transmembrane transport of exogenous molecules352US 5,416,016 APurdue Research Foundation · 1995
- Method for enhanced transmembrane transport of exogenous molecules302US 5,108,921 APurdue Research Foundation · 1992
- Periodic constriction of vessels to treat ischemic tissue245US 6,544,543 B1Advanced Cardiovascular Systems, Inc. · 2003
- Elongated and multiple spacers in activatible prodrugs154US 7,223,837 B2Syntarga B.V. · 2007
- Pretargeting methods and compounds125US 6,217,869 B1NeoRx Corporation · 2001